Congressional focus on the underlying drivers of health care costs is accelerating, with increasing attention on hospital pricing, market consolidation, and structural inefficiencies that directly impact employer-sponsored health plans.

The House Ways and Means Committee recently convened a hearing to examine these issues, featuring testimony from executives representing major U.S. health systems. In conjunction with the hearing, the American Benefits Council reiterated its policy priorities, emphasizing the need for reforms that strengthen transparency, promote competition, and better align incentives across the health care system.
Hospital pricing continues to be a central concern for policymakers. Hospital care represents the largest share of overall health care spending in the United States and remains a primary driver of rising costs for employer-sponsored plans. Lawmakers are increasingly focused on the structural dynamics contributing to these costs, including provider consolidation, vertical integration, and contracting practices that may limit competition and sustain higher prices.

At the center of current policy discussions is the concept of site-neutral payment reform. Under the existing system, hospitals often receive higher reimbursement rates for services delivered in hospital-owned outpatient departments than for identical services performed in independent physician offices. Policymakers argue that these payment disparities create incentives for health systems to acquire physician practices and shift care to higher-cost settings, thereby increasing overall spending. During the hearing, several lawmakers characterized these dynamics as a significant driver of both cost growth and consolidation. Hospital leaders acknowledged that certain pricing inconsistencies may warrant review, while also emphasizing the additional operational costs associated with hospital-based care, including emergency services and uncompensated care.

Another focal point of the hearing was the 340B drug pricing program. The program allows eligible hospitals and providers to purchase outpatient drugs at discounted prices, with the intent of supporting care for underserved populations. However, policymakers and employer groups have raised concerns about the program’s expansion and the lack of transparency surrounding how savings are used. During the hearing, lawmakers questioned whether 340B-related savings are consistently used to benefit patients or whether they contribute to broader cost pressures in the system. Hospital representatives indicated that program revenues are often used to offset administrative expenses and the costs associated with treating Medicaid populations, though questions remain about overall accountability and impact.

Price transparency also featured prominently in the discussion. Lawmakers highlighted significant variation in pricing across providers, including instances where hospital charges far exceed Medicare reimbursement levels. While hospital executives attributed these differences to factors such as quality of care and operational complexity, policymakers emphasized the need for more consistent and accessible pricing data to enable employers and consumers to make more informed decisions.

The hearing further underscored concerns about the impact of consolidation and vertical integration within the health care market. Lawmakers noted the continued growth of large health systems and the expansion of hospital-owned outpatient facilities, which may command higher reimbursement rates and reduce competitive pressure in local markets. These trends have been closely linked to rising costs for employer-sponsored coverage.
Although there was broad agreement that affordability remains a critical issue, the hearing also reflected differing policy perspectives. Republican lawmakers largely focused on targeted structural reforms, including site-neutral payment policies and increased oversight of the 340B program. Democratic lawmakers emphasized broader affordability challenges, including coverage dynamics and federal funding considerations, while also acknowledging that certain targeted reforms may warrant further evaluation.

These discussions are occurring alongside broader legislative and advocacy efforts aimed at addressing the root causes of health care cost growth. Proposals under consideration include expanding site-neutral payment policies, enhancing transparency requirements for providers and intermediaries, modernizing the 340B program, and limiting anti-competitive contracting practices that can restrict employer flexibility in plan design. For employers, the evolving policy landscape signals a continued shift toward addressing underlying cost drivers rather than redistributing costs across stakeholders. Changes in reimbursement structures, transparency requirements, and provider market dynamics have the potential to influence employer health plan costs, network strategies, and vendor relationships in the years ahead.